Gritstone Oncology Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. I'm Shelby Barada with JPMorgan's Healthcare Investment Banking team. I'm very pleased to be here with Dr. Andrew Allen, President and Co-Founder and CEO of Gritstone Oncology. The breakout following this will be held immediately following the presentation in the Olympic room. And with that, over to Andrew.
Thanks, Shelby. Good morning, everybody. Indeed, I'm Andrew Allen, I'm one of the Co-founders, the CEO of Gritstone Oncology. We're a public company. We went public in September of 2018, and I'll be making some forward-looking statements.
Gritstone Oncology is now 4.5 years old. We have around 170 employees. And we're a company that began life focused on deliver antigen-based immunotherapies to cancer patients. We now have 2 neoantigen-based immunotherapies in Phase I clinical trials. And I will show you a little data from those trials today.
If you
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |